Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06202248
Other study ID # CTP-PRST-00
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 12, 2024
Est. completion date June 2027

Study information

Verified date May 2024
Source Alpha Tau Medical LTD.
Contact Liron Dimnik
Phone +972542688602
Email LironD@alphatau.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center clinical study enrolling up to 10 participants. The purpose of this study is to assess the feasibility and safety of intratumoral DaRT seeds implantation for the treatment of locally recurrent prostate cancer. Secondary objectives are to 1. To evaluate feasibility of interstitial radiotherapy using DaRT seeds. Feasibility will be determined according to the rate of successful placement of DaRT seeds via imaging [Timeframe: immediately following the insertion procedure 2. To assess the impact of DaRT seeds on patient reported quality of life.


Description:

This study is a prospective multicenter, single arm, open label , interventional clinical study to assess the feasibility and safety of intratumoral Alpha DaRT seeds for the treatment of men with non metastatic locally recurrent prostate cancer. Diffusing Alpha emitters Radiation Therapy (DaRT). Treatment will be delivered through radioactive sources [Ra-224 containing Stainless steel 316LVM tubes- (Alpha DaRT seeds)] inserted into the tumors. The purpose of this study is to assess the feasibility and safety of intratumoral DaRT seeds implantation for the treatment of locally recurrent prostate cancer. The secondary objectives is 1. To evaluate feasibility of interstitial radiotherapy using DaRT seeds. Feasibility will be determined according to the rate of successful placement of DaRT seeds via imaging [Timeframe: immediately following the insertion procedure 2. To assess the impact of DaRT seeds on patient reported quality of life.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date June 2027
Est. primary completion date June 2027
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 120 Years
Eligibility Inclusion Criteria: - Histologically confirmed locally recurrent prostate adenocarcinoma cancer confined to at least 1 hemi-gland with concordant pathology and imaging findings within 6 months prior to consenting - Targetable lesion by either PSMA PET-CT according to PERCIST v1.0 or by multiparametric MRI according RECIST v1.1 - Patient being considered for focal salvage brachytherapy - Lesion size = 3 cm in the longest diameter - Target lesion technically amenable for full tumor coverage with the Alpha DaRT seeds - Pre-salvage PSA level (rPSA) below <10 ng/ml - Age = 18 years old - ECOG Performance Status Scale = 2 - Subjects' life expectancy is more than 6 months - Negative metastatic workup on at least standard imaging (CT CAP and bone scan). Other metastatic screening studies allowed in lieu of standard imaging including multiparametric MRI prostate/whole body, PSMA PET, F18 PET or Axumin PET within 3 months before visit 0 - Platelet count =100,000/mm3 - Subjects are willing and able to sign an informed consent form. Exclusion Criteria: - N1 or M1 disease - Prior TURP or prostate surgery - Inability to undergo multiparametric MRI (i.e. permanent implanted device incompatible with MRI) - Inability to undergo general or spinal anesthesia - Prior androgen deprivation therapy or systemic chemotherapy for prostate cancer within 3 months before visit 0. - Previous diagnosis of other malignancy < 3 years of enrollment (excluding non-melanomatous skin cancer) - Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT - High probability of protocol non-compliance (in opinion of investigator) - Subjects not willing to sign an informed consent - Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Experimental: DaRT seeds
Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds

Locations

Country Name City State
Israel RAMBAM Health Care Campus Haifa

Sponsors (1)

Lead Sponsor Collaborator
Alpha Tau Medical LTD.

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of intratumoral DaRT seeds implantation To evaluate feasibility of interstitial radiotherapy using DaRT seeds. Feasibility will be determined according to the rate of successful placement of DaRT seeds via imaging immediately following the insertion procedure
See also
  Status Clinical Trial Phase
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT00673205 - (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer Phase 3
Completed NCT00672282 - Casodex vs Placebo in Non-Metastatic Early Prostate Cancer Phase 3
Recruiting NCT01317043 - A Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy Phase 2
Completed NCT06204302 - An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
Completed NCT00239291 - Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer Phase 1/Phase 2
Recruiting NCT04049747 - Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer N/A
Active, not recruiting NCT05617885 - Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer Phase 1/Phase 2
Completed NCT00657904 - Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer Phase 3